{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:54:28Z","timestamp":1781610868827,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022026","name":"Aswan University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rheumatoid Arthritis (RA) is a prevalent autoimmune disease affecting approximately 84,338 individuals in Egypt. Genetic predispositions, such as the PTPN22 and PADI4 genes, are linked to RA risk. PTPN22, a protein tyrosine phosphatase, a regulator of T-cell receptor signalling and PADI4, which is involved in citrullination, have shown varying levels of association with RA across populations. Studies have been inconclusive regarding their roles in RA susceptibility, progression, and activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A total of 240 participants were included in this study, RA patients and healthy controls from Aswan, Egypt. Genomic analysis was conducted to evaluate PTPN22 and PADI4 polymorphisms and their associations with RF and ACPA, Also, their correlation with disease activity markers, such as ESR, CRP, PGA and the Disease Activity Score (DAS28).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No significant association between PTPN22 and RA with p value\u2009\u2265\u20090.05 with good matching regarding age and sex. However, PTPN22 significantly correlated with RF and ACPA, with p-value of 0.006 and &lt;\u20090.001, respectively, suggesting its diagnostic value in RA. No significant associations were found between PTPN22 and disease activity markers such as the ESR and CRP. In contrast, PADI4 levels were elevated in the control groups with p value\u2009&lt;\u20090.001 which is against the study hypothesis, which conflicts with findings from other studies. Despite this, PADI4 demonstrated greater specificity (73.3%), in RA diagnosis than did PTPN22 (45.3%), making it a potential diagnostic marker in combination with RF and ACPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study revealed no significant associations between PTPN22 or PADI4 polymorphisms and RA susceptibility in the Aswan population. However, both genes were correlated with diagnostic markers such as RF and ACPA. The PADI4 has potential as a diagnostic marker with high specificity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-025-00566-z","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:33:42Z","timestamp":1758551622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Associations of PTPN22 and PADI4 polymorphisms with rheumatoid arthritis in ASWAN"],"prefix":"10.1186","volume":"9","author":[{"given":"Khaled A. A.","family":"Abdelgalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma H.","family":"El Nouby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay I.","family":"Aglan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"566_CR1","doi-asserted-by":"publisher","first-page":"19297","DOI":"10.1038\/s41598-022-22310-0","volume":"12","author":"S Mousavi","year":"2022","unstructured":"Mousavi S, Nejadghaderi S, Khabbazi A, et al. The burden of rheumatoid arthritis in the middle East and North Africa region, 1990\u20132019. Sci Rep. 2022;12:19297.","journal-title":"Sci Rep"},{"key":"566_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00281-022-00912-0","volume":"44","author":"L Padyukov","year":"2022","unstructured":"Padyukov L. Genetics of rheumatoid arthritis. Semin Immunopathol. 2022;44:47\u201362.","journal-title":"Semin Immunopathol"},{"key":"566_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/rheumatology\/ken005","volume":"47","author":"J Bowes","year":"2008","unstructured":"Bowes J, Barton A. Recent advances in the genetics of RA susceptibility. Rheumatology. 2008;47:399\u2013402.","journal-title":"Rheumatology"},{"key":"566_CR4","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/art.21049","volume":"52","author":"A Hinks","year":"2005","unstructured":"Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths C, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthr Rhuem. 2005;52:1694\u20139.","journal-title":"Arthr Rhuem"},{"key":"566_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.0105-2896.2005.00243.x","volume":"204","author":"PK Gregersen","year":"2005","unstructured":"Gregersen PK. Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond. Immunol Rev. 2005;204:74\u201386.","journal-title":"Immunol Rev"},{"key":"566_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/rheumatology\/ken192","volume":"47","author":"V Goeb","year":"2008","unstructured":"Goeb V, Dieude P, Daveau R, Thomas-L\u2019Otellier M, Jouen F, Hau F, et al. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis. Rheumatology. 2008;47:1208\u201312.","journal-title":"Rheumatology"},{"key":"566_CR7","doi-asserted-by":"crossref","unstructured":"Johansson M, Arlestig L, Hallmans G, Rantap\u00e4\u00e4-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Research & Therapy. 2006;8:R19.","DOI":"10.1186\/ar1868"},{"key":"566_CR8","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1136\/ard.2006.067892","volume":"66","author":"BA Lie","year":"2007","unstructured":"Lie BA, Viken MK, \u00d8deg\u00e5rd S, van der Heijde D, Landew\u00e9 R, Uhlig T, et al. Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2007;66:1604\u20139.","journal-title":"Ann Rheum Dis"},{"key":"566_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/ard.2007.071662","volume":"67","author":"EW Karlson","year":"2008","unstructured":"Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, et al. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis. 2008;67:358\u201363.","journal-title":"Ann Rheum Dis"},{"key":"566_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/gene.2012.46","volume":"13","author":"J Zheng","year":"2012","unstructured":"Zheng J, Ibrahim S, Petersen F, Yu X. Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue. Genes Immun. 2012;13:641\u201352.","journal-title":"Genes Immun"},{"key":"566_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gene.2003.12.038","volume":"330","author":"S Chavanas","year":"2004","unstructured":"Chavanas S, M\u00e9chin MC, Takahara H, Kawada A, Nachat R, Serre G, et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved noncoding segments and a new human gene, PADI6. Gene. 2004;330:19\u201327.","journal-title":"Gene"},{"key":"566_CR12","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/art.21309","volume":"52","author":"K Ikari","year":"2005","unstructured":"Ikari K, Kuwahara M, Nakamura T, Momohara S, Hara M, Yamanaka H, et al. Association between PADI4 and rheumatoid arthritis: A replication study. Arthr Rhuem. 2005;52:3054\u20137.","journal-title":"Arthr Rhuem"},{"key":"566_CR13","doi-asserted-by":"crossref","unstructured":"Too CL, Murad S, Dhaliwal JS, Larsson P, Jiang X, Ding B, et al. Polymorphisms in peptidylarginine deiminase associate with rheumatoid arthritis in diverse Asian populations: evidence from MYEIRA study and meta-analysis. Arthritis Research & Therapy. 2012;14:R250.","DOI":"10.1186\/ar4093"},{"key":"566_CR14","first-page":"377","volume":"32","author":"Y Du","year":"2014","unstructured":"Du Y, Liu X, Guo JP, Liu X, Li R, Zhao Y, et al. Association between PADI4 gene polymorphisms and anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis in a large Chinese Han cohort. Clin Experimental Rheumatol. 2014;32:377\u201382.","journal-title":"Clin Experimental Rheumatol"},{"key":"566_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/ard.2009.111294","volume":"69","author":"ML Burr","year":"2010","unstructured":"Burr ML, Naseem H, Hinks A, Eyre S, Gibbons LJ, Bowes J, et al. The PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Ann Rheum Dis. 2010;69:666\u201370.","journal-title":"Ann Rheum Dis"},{"key":"566_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.20169","volume":"50","author":"A Barton","year":"2004","unstructured":"Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, John S, et al. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated united Kingdom population. Arthr Rhuem. 2004;50:1117\u201321.","journal-title":"Arthr Rhuem"},{"key":"566_CR17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ng.2462","volume":"44","author":"S Eyre","year":"2012","unstructured":"Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44:1336\u201340.","journal-title":"Nat Genet"},{"key":"566_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00296-009-0919-2","volume":"30","author":"N Sahin","year":"2009","unstructured":"Sahin N, Gunduz F, Inanc N, et al. No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey. Rheumatol Int. 2009;30:81\u20133.","journal-title":"Rheumatol Int"},{"issue":"3","key":"566_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/08916934.2015.1134514","volume":"49","author":"G Nabi","year":"2016","unstructured":"Nabi G, Akhter N, Wahid M, Bhatia K, Mandal RK, Dar SA, Jawed A, Haque S. Meta-analysis reveals PTPN22 1858\u00a0C\/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian population. Autoimmunity. 2016;49(3):197\u2013210. https:\/\/doi.org\/10.3109\/08916934.2015.1134514.","journal-title":"Autoimmunity"},{"key":"566_CR20","doi-asserted-by":"crossref","unstructured":"Totaro MC et al. PTPN22 1858C\u2009>\u2009T polymorphism distribution in Europe and association with rheumatoid arthritis: Case\u2013control study and meta-analysis. PLoS ONE. 2011;6(9):e24292.","DOI":"10.1371\/journal.pone.0024292"},{"issue":"1","key":"566_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cellimm.2014.05.003","volume":"290","author":"A Salama","year":"2014","unstructured":"Salama A, et al. Protein tyrosine phosphatase nonreceptor type 22 (PTPN22)\u2009+\u20091858 C\u2009>\u2009T gene polymorphism in Egyptian cases with rheumatoid arthritis. Cell Immunol. 2014;290(1):62\u20135. https:\/\/doi.org\/10.1016\/j.cellimm.2014.05.003.","journal-title":"Cell Immunol"},{"issue":"6","key":"566_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.humimm.2016.04.018","volume":"77","author":"MM Hegab","year":"2016","unstructured":"Hegab MM, et al. CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians. Hum Immunol. 2016;77(6):522\u20136. https:\/\/doi.org\/10.1016\/j.humimm.2016.04.018.","journal-title":"Hum Immunol"},{"issue":"4","key":"566_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.35248\/2155-9889.20.11.586","volume":"11","author":"I Allam","year":"2020","unstructured":"Allam I, Gharnaout M, Louahchi S, Raaf N, Kheldoun N, Ladjouze A, Berkani L. Association study of PTPN22 (rs2476601) and PADI4 (rs2240340) polymorphisms with rheumatoid arthritis in Algerian population. J Clin Cell Immunol. 2020;11(4):586. https:\/\/doi.org\/10.35248\/2155-9889.20.11.586.","journal-title":"J Clin Cell Immunol"},{"issue":"1","key":"566_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12920-023-01532-9IF","volume":"16","author":"Z Bagheri-Hosseinabadi","year":"2023","unstructured":"Bagheri-Hosseinabadi Z, Mirzaei MR, Esmaeili O, Asadi F, Ahmadinia H, Shamsoddini B, Abbasifard M. Implications of peptidyl arginine deiminase 4 gene transcription and polymorphisms in susceptibility to rheumatoid arthritis in an Iranian population. BMC Med Genom. 2023;16(1):104. https:\/\/doi.org\/10.1186\/s12920-023-01532-9IF:2.1Q3.","journal-title":"BMC Med Genom"},{"issue":"3","key":"566_CR25","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar2214","volume":"9","author":"H Kokkonen","year":"2007","unstructured":"Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858\u00a0C\/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in Northern Sweden. Arthritis Res Ther. 2007;9(3):R56.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"566_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s10067-015-3082-z","volume":"35","author":"N Umeda","year":"2016","unstructured":"Umeda N, Matsumoto I, Kawaguchi H, Kurashima Y, Kondo Y, Tsuboi H, et al. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases. Clin Rheumatol. 2016;35(5):1181\u20138. https:\/\/doi.org\/10.1007\/s10067-015-3082-z.","journal-title":"Clin Rheumatol"},{"issue":"21","key":"566_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.21608\/zumj.2021.48120.198","volume":"29","author":"A Ahmed","year":"2023","unstructured":"Ahmed A, El-Gawish M, Esh A, Makram W. Serum peptidyl arginine Deiminase-4 (PADI4) antibodies in rheumatoid arthritis and their correlation with disease activity. Zagazig Univ Med J. 2023;29(21):80\u20136. https:\/\/doi.org\/10.21608\/zumj.2021.48120.198.","journal-title":"Zagazig Univ Med J"},{"key":"566_CR28","doi-asserted-by":"publisher","first-page":"110164","DOI":"10.1016\/j.abb.2024.110164","volume":"761","author":"S Panchalingam","year":"2024","unstructured":"Panchalingam S, Jayaraman M, Jeyaraman J. Harnessing marine natural products to inhibit PAD4 triple mutant: A structure-based virtual screening approach for rheumatoid arthritis therapy. Arch Biochem Biophys. 2024;761:110164. https:\/\/doi.org\/10.1016\/j.abb.2024.110164.","journal-title":"Arch Biochem Biophys"},{"issue":"2","key":"566_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jbspin.2011.07.006","volume":"79","author":"SH Abd-Allah","year":"2012","unstructured":"Abd-Allah SH, et al. PADI4 polymorphisms and related haplotypes in rheumatoid arthritis patients. Joint Bone Spine. 2012;79(2):124\u20138. https:\/\/doi.org\/10.1016\/j.jbspin.2011.07.006.","journal-title":"Joint Bone Spine"},{"key":"566_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejr.2018.06.002","volume":"41","author":"N Hussein","year":"2019","unstructured":"Hussein N, et al. Peptidyl-arginine deiminase-type IV as a diagnostic and prognostic marker in rheumatoid arthritis patients. Egypt Rheumatologist. 2019;41:87\u201391.","journal-title":"Egypt Rheumatologist"},{"issue":"8","key":"566_CR31","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.3390\/ijms24087586","volume":"24","author":"T Budlewski","year":"2023","unstructured":"Budlewski T, Sarnik J, Galita G, Dragan G, Brzezi\u0144ska O, Pop\u0142awska M, Pop\u0142awski T, Makowska J. SNP in PTPN22, PADI4, and STAT4 but not TRAF1 and CD40 increase the risk of rheumatoid arthritis in Polish population. Int J Mol Sci. 2023;24(8):7586. https:\/\/doi.org\/10.3390\/ijms24087586.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"566_CR32","doi-asserted-by":"publisher","first-page":"11882","DOI":"10.1038\/s41598-022-15726-1","volume":"12","author":"M Ciesla","year":"2022","unstructured":"Ciesla M, Kolarz B, Darmochwal-Kolarz D. The lack of association between PADI4_94 or PADI4_104 polymorphisms and RF, ACPA and anti-PAD4 in patients with rheumatoid arthritis. Sci Rep. 2022;12(1):11882. https:\/\/doi.org\/10.1038\/s41598-022-15726-1.","journal-title":"Sci Rep"},{"issue":"B","key":"566_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3889\/oamjms.2021.6472","volume":"9","author":"A Issilbayeva","year":"2021","unstructured":"Issilbayeva A, Kushugulova A, Meiramova A, Kozhakhmetov S, Akhmetova Z, Nurgaziyev M, Ainabekova B. Epidemiological trends of rheumatoid arthritis and PADI4, PTPN22, and HLA-DRB9 genes distribution in the Kazakhstan 120 population. Open Access Macedonian J Med Sci. 2021;9(B):747\u201355. https:\/\/doi.org\/10.3889\/oamjms.2021.6472.","journal-title":"Open Access Macedonian J Med Sci"},{"key":"566_CR34","doi-asserted-by":"publisher","first-page":"707690","DOI":"10.3389\/fimmu.2021.707690","volume":"12","author":"L Massarenti","year":"2021","unstructured":"Massarenti L, Enevold C, Damgaard D, \u00d8dum N, Garred P, Frisch M, Shelef MA, Jacobsen S, Nielsen CH. PADI4 polymorphisms confer risk of Anti-CCP-Positive rheumatoid arthritis in synergy with HLA-DRB1*04 and smoking. Front Immunol. 2021;12:707690. https:\/\/doi.org\/10.3389\/fimmu.2021.707690.","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1186\/s41927-025-00578-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000}}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00566-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:23:24Z","timestamp":1781609004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-025-00566-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00566-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5784255\/v1","asserted-by":"object"}]},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s41927-025-00578-9","URL":"https:\/\/doi.org\/10.1186\/s41927-025-00578-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal and written consent obtained from all patients before they were involved in the study. The steps of the study, the aim of the study, and the potential benefits and hazards will all be discussed with the cases. The confidentiality of all the data will be ensured. The patients had the right to withdraw from the study at any time without giving any reason. Aswan faculty of medicine ethical committee (Graduate studies & research office, Aswan faculty of medicine, Ethics committee board, Aswan University) Had Reviewed and Approved to conduct the above mentioned clinical trial and the study in compliance with the Helsinki Declaration. On IRB Ref NO: Asw.Uni. \/ 678 \/ 10 \/ 22. Site of the study: Aswan Faulty of Medicine. Chairman of ethical committee Board: Prof. Mohamed ZaKi Ali Ahmed (Dean of Aswan faulty of medicine) -Prof. Moustafa Adam Ali (VICE DEAN for Graduate Studies and Research Affairs).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}